Study of Investigational Drug NS-229 to Treat EGPA

Purpose: The main purpose of this study is to learn if the investigational drug NS-229 is safe and effective in treating adults with EGPA that returns (relapses) or has not responded to treatment. Participants are randomly assigned to receive either NS-229 or a placebo, taken by mouth; and have 11 study visits at the Perelman Center.

ClinicalTrials.gov ID: NCT06046222

Study Duration: 9 months

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA)